Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90
Background Precursor B‐cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non‐Hodgkin lymphoma (NHL). The purpose of our study was to investigate frequency and clinicopathological features of PBLL in children and to test prospectively the efficacy of an ALL‐type therapy for treatment...
Gespeichert in:
| Veröffentlicht in: | Medical and pediatric oncology 2000-07, Vol.35 (1), p.20-27 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 27 |
|---|---|
| container_issue | 1 |
| container_start_page | 20 |
| container_title | Medical and pediatric oncology |
| container_volume | 35 |
| creator | Neth, Olaf Seidemann, Kathrin Jansen, Petra Mann, Georg Tiemann, Markus Ludwig, Wolf-Dieter Riehm, Hansjörg Reiter, Alfred |
| description | Background
Precursor B‐cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non‐Hodgkin lymphoma (NHL). The purpose of our study was to investigate frequency and clinicopathological features of PBLL in children and to test prospectively the efficacy of an ALL‐type therapy for treatment of these patients.
Procedure
From October, 1986, to March, 1995, 1,075 patients up to 18 years of age suffering from all kinds of NHL were registered in the two consecutive multicenter studies NHL‐BFM 86 and 90. Of these, 27 patients were diagnosed with PBLL. Twenty‐one PBLL patients were treated according to a BFM‐ALL‐type protocol: an eight‐drug induction over 9 weeks was followed by an 8‐week consolidation including methotrexate 5 g/m2 ×4. Patients in stages I and II continued with maintenance up to a total therapy duration of 24 months, whereas patients in stages III and IV received an additional eight‐drug intensification and cranial radiotherapy (12 Gy for prophylaxis) after consolidation. Six PBLL patients were treated according to the BFM‐protocol for B‐NHL, stratified according to stage and tumor load and consisiting of two to six 5‐day courses of chemotherapy.
Results
The median age of the 27 patients with PBLL (18 boys, 9 girls) was 6.2 (range 0.7–15) years. Stages (St. Jude) were: I (n = 3), II (n = 7), III (n = 9), and IV (n = 8). Twenty‐one PBLL patients had nodal disease, 6 patients had subcutaneous manifestations, and 8 patients had bone marrow disease ( |
| doi_str_mv | 10.1002/1096-911X(200007)35:1<20::AID-MPO4>3.0.CO;2-L |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71237005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71237005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4814-62a2fcbcbd7e0d1cbdae1f71181b68200f1701c6b735d56829792ac0aae44f4f3</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhi0EYmXwF1AuEGLSUvyRxElBk7bAPqS03QVoaDdHjuOoBicpdiLob-BP4zTV4IILLFm2jx-_Pj6vEYoJnhOM6VuCsyTMCPnyhmLf-AmLF-Q9xYvF-c2HcHm7js7YHM_z9TsaFo_Q7IF_jGYYZ2lIYkaP0DPnvvrjWcbTp-iI4DT16myGft1aJQfrOhtchFIZE5hds910pRGu1_KwakSg20ButKk2XVcFovW96oxyUrVSLYLc6FZLYYJaiX6wyp0GvfXTRrX96R73scH0btTprRbGBavrIry4XAZpsgcy_Bw9qf2GenEYj9Hny4-f8uuwWF_d5OdFKKOURGFCBa1lKcuKK1wRPwpFak5ISsok9VWqCcdEJiVncRX7SMYzKiQWQkVRHdXsGL2edLe2-z4o10Oj3fh20apucMAJZRzj2IPLCZS2c86qGrZWN8LugGAY3YGx2jBWGyZ3gMVA_BzAuwOjO8AAQ74GCoXXe3m4eCgbVf2lNtnhgVcHQDhfzdqKVmr3h4tZgknqsdWE_dBG7f4_qX_ktF97wXAS1K5XPx8Ehf0GCWc8hrvVFYy_5764o3DPfgOQkcL4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71237005</pqid></control><display><type>article</type><title>Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Neth, Olaf ; Seidemann, Kathrin ; Jansen, Petra ; Mann, Georg ; Tiemann, Markus ; Ludwig, Wolf-Dieter ; Riehm, Hansjörg ; Reiter, Alfred</creator><creatorcontrib>Neth, Olaf ; Seidemann, Kathrin ; Jansen, Petra ; Mann, Georg ; Tiemann, Markus ; Ludwig, Wolf-Dieter ; Riehm, Hansjörg ; Reiter, Alfred</creatorcontrib><description>Background
Precursor B‐cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non‐Hodgkin lymphoma (NHL). The purpose of our study was to investigate frequency and clinicopathological features of PBLL in children and to test prospectively the efficacy of an ALL‐type therapy for treatment of these patients.
Procedure
From October, 1986, to March, 1995, 1,075 patients up to 18 years of age suffering from all kinds of NHL were registered in the two consecutive multicenter studies NHL‐BFM 86 and 90. Of these, 27 patients were diagnosed with PBLL. Twenty‐one PBLL patients were treated according to a BFM‐ALL‐type protocol: an eight‐drug induction over 9 weeks was followed by an 8‐week consolidation including methotrexate 5 g/m2 ×4. Patients in stages I and II continued with maintenance up to a total therapy duration of 24 months, whereas patients in stages III and IV received an additional eight‐drug intensification and cranial radiotherapy (12 Gy for prophylaxis) after consolidation. Six PBLL patients were treated according to the BFM‐protocol for B‐NHL, stratified according to stage and tumor load and consisiting of two to six 5‐day courses of chemotherapy.
Results
The median age of the 27 patients with PBLL (18 boys, 9 girls) was 6.2 (range 0.7–15) years. Stages (St. Jude) were: I (n = 3), II (n = 7), III (n = 9), and IV (n = 8). Twenty‐one PBLL patients had nodal disease, 6 patients had subcutaneous manifestations, and 8 patients had bone marrow disease (<25% blasts). All patients achieved remission. With a median follow‐up time of 4.25 years, the estimated probability for event‐free survival (pEFS) at 10 years for the total group was 0.73 (SE 0.10). Five patients (2, 1, 1, and 1 patients at stages I, II, III, and IV, respectively) relapsed: 2 of 21 patients who were treated according to the ALL strategy and 3 of 6 who were treated according to the B‐NHL‐protocol.
Conclusions
PBLL accounts for 2.5% of childhood NHL. An ALL‐type therapy strategy appears to be superior to a short‐pulse B‐NHL protocol. Med. Pediatr. Oncol. 35:20–27, 2000. © 2000 Wiley‐Liss, Inc.</description><identifier>ISSN: 0098-1532</identifier><identifier>EISSN: 1096-911X</identifier><identifier>DOI: 10.1002/1096-911X(200007)35:1<20::AID-MPO4>3.0.CO;2-L</identifier><identifier>PMID: 10881003</identifier><identifier>CODEN: MPONDB</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adolescent ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asparaginase - administration & dosage ; Austria - epidemiology ; B-Lymphocytes ; Biological and medical sciences ; Chemotherapy ; Child ; Child, Preschool ; childhood therapy ; Cohort Studies ; Daunorubicin - administration & dosage ; Disease-Free Survival ; Female ; Germany - epidemiology ; Humans ; Infant ; lymphoblastic lymphoma ; Male ; Medical sciences ; Multicenter Studies as Topic ; Neoplasm Staging ; Pharmacology. Drug treatments ; precursor B-cell ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality ; Prednisone - administration & dosage ; Prospective Studies ; Registries ; Survival Analysis ; Vincristine - administration & dosage</subject><ispartof>Medical and pediatric oncology, 2000-07, Vol.35 (1), p.20-27</ispartof><rights>Copyright © 2000 Wiley‐Liss, Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright 2000 Wiley-Liss, Inc.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4814-62a2fcbcbd7e0d1cbdae1f71181b68200f1701c6b735d56829792ac0aae44f4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F1096-911X%28200007%2935%3A1%3C20%3A%3AAID-MPO4%3E3.0.CO%3B2-L$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F1096-911X%28200007%2935%3A1%3C20%3A%3AAID-MPO4%3E3.0.CO%3B2-L$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1536018$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10881003$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Neth, Olaf</creatorcontrib><creatorcontrib>Seidemann, Kathrin</creatorcontrib><creatorcontrib>Jansen, Petra</creatorcontrib><creatorcontrib>Mann, Georg</creatorcontrib><creatorcontrib>Tiemann, Markus</creatorcontrib><creatorcontrib>Ludwig, Wolf-Dieter</creatorcontrib><creatorcontrib>Riehm, Hansjörg</creatorcontrib><creatorcontrib>Reiter, Alfred</creatorcontrib><title>Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90</title><title>Medical and pediatric oncology</title><addtitle>Med. Pediatr. Oncol</addtitle><description>Background
Precursor B‐cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non‐Hodgkin lymphoma (NHL). The purpose of our study was to investigate frequency and clinicopathological features of PBLL in children and to test prospectively the efficacy of an ALL‐type therapy for treatment of these patients.
Procedure
From October, 1986, to March, 1995, 1,075 patients up to 18 years of age suffering from all kinds of NHL were registered in the two consecutive multicenter studies NHL‐BFM 86 and 90. Of these, 27 patients were diagnosed with PBLL. Twenty‐one PBLL patients were treated according to a BFM‐ALL‐type protocol: an eight‐drug induction over 9 weeks was followed by an 8‐week consolidation including methotrexate 5 g/m2 ×4. Patients in stages I and II continued with maintenance up to a total therapy duration of 24 months, whereas patients in stages III and IV received an additional eight‐drug intensification and cranial radiotherapy (12 Gy for prophylaxis) after consolidation. Six PBLL patients were treated according to the BFM‐protocol for B‐NHL, stratified according to stage and tumor load and consisiting of two to six 5‐day courses of chemotherapy.
Results
The median age of the 27 patients with PBLL (18 boys, 9 girls) was 6.2 (range 0.7–15) years. Stages (St. Jude) were: I (n = 3), II (n = 7), III (n = 9), and IV (n = 8). Twenty‐one PBLL patients had nodal disease, 6 patients had subcutaneous manifestations, and 8 patients had bone marrow disease (<25% blasts). All patients achieved remission. With a median follow‐up time of 4.25 years, the estimated probability for event‐free survival (pEFS) at 10 years for the total group was 0.73 (SE 0.10). Five patients (2, 1, 1, and 1 patients at stages I, II, III, and IV, respectively) relapsed: 2 of 21 patients who were treated according to the ALL strategy and 3 of 6 who were treated according to the B‐NHL‐protocol.
Conclusions
PBLL accounts for 2.5% of childhood NHL. An ALL‐type therapy strategy appears to be superior to a short‐pulse B‐NHL protocol. Med. Pediatr. Oncol. 35:20–27, 2000. © 2000 Wiley‐Liss, Inc.</description><subject>Adolescent</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asparaginase - administration & dosage</subject><subject>Austria - epidemiology</subject><subject>B-Lymphocytes</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>childhood therapy</subject><subject>Cohort Studies</subject><subject>Daunorubicin - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Germany - epidemiology</subject><subject>Humans</subject><subject>Infant</subject><subject>lymphoblastic lymphoma</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Multicenter Studies as Topic</subject><subject>Neoplasm Staging</subject><subject>Pharmacology. Drug treatments</subject><subject>precursor B-cell</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</subject><subject>Prednisone - administration & dosage</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Survival Analysis</subject><subject>Vincristine - administration & dosage</subject><issn>0098-1532</issn><issn>1096-911X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl1v0zAUhi0EYmXwF1AuEGLSUvyRxElBk7bAPqS03QVoaDdHjuOoBicpdiLob-BP4zTV4IILLFm2jx-_Pj6vEYoJnhOM6VuCsyTMCPnyhmLf-AmLF-Q9xYvF-c2HcHm7js7YHM_z9TsaFo_Q7IF_jGYYZ2lIYkaP0DPnvvrjWcbTp-iI4DT16myGft1aJQfrOhtchFIZE5hds910pRGu1_KwakSg20ButKk2XVcFovW96oxyUrVSLYLc6FZLYYJaiX6wyp0GvfXTRrX96R73scH0btTprRbGBavrIry4XAZpsgcy_Bw9qf2GenEYj9Hny4-f8uuwWF_d5OdFKKOURGFCBa1lKcuKK1wRPwpFak5ISsok9VWqCcdEJiVncRX7SMYzKiQWQkVRHdXsGL2edLe2-z4o10Oj3fh20apucMAJZRzj2IPLCZS2c86qGrZWN8LugGAY3YGx2jBWGyZ3gMVA_BzAuwOjO8AAQ74GCoXXe3m4eCgbVf2lNtnhgVcHQDhfzdqKVmr3h4tZgknqsdWE_dBG7f4_qX_ktF97wXAS1K5XPx8Ehf0GCWc8hrvVFYy_5764o3DPfgOQkcL4</recordid><startdate>200007</startdate><enddate>200007</enddate><creator>Neth, Olaf</creator><creator>Seidemann, Kathrin</creator><creator>Jansen, Petra</creator><creator>Mann, Georg</creator><creator>Tiemann, Markus</creator><creator>Ludwig, Wolf-Dieter</creator><creator>Riehm, Hansjörg</creator><creator>Reiter, Alfred</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200007</creationdate><title>Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90</title><author>Neth, Olaf ; Seidemann, Kathrin ; Jansen, Petra ; Mann, Georg ; Tiemann, Markus ; Ludwig, Wolf-Dieter ; Riehm, Hansjörg ; Reiter, Alfred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4814-62a2fcbcbd7e0d1cbdae1f71181b68200f1701c6b735d56829792ac0aae44f4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adolescent</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asparaginase - administration & dosage</topic><topic>Austria - epidemiology</topic><topic>B-Lymphocytes</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>childhood therapy</topic><topic>Cohort Studies</topic><topic>Daunorubicin - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Germany - epidemiology</topic><topic>Humans</topic><topic>Infant</topic><topic>lymphoblastic lymphoma</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Multicenter Studies as Topic</topic><topic>Neoplasm Staging</topic><topic>Pharmacology. Drug treatments</topic><topic>precursor B-cell</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality</topic><topic>Prednisone - administration & dosage</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Survival Analysis</topic><topic>Vincristine - administration & dosage</topic><toplevel>online_resources</toplevel><creatorcontrib>Neth, Olaf</creatorcontrib><creatorcontrib>Seidemann, Kathrin</creatorcontrib><creatorcontrib>Jansen, Petra</creatorcontrib><creatorcontrib>Mann, Georg</creatorcontrib><creatorcontrib>Tiemann, Markus</creatorcontrib><creatorcontrib>Ludwig, Wolf-Dieter</creatorcontrib><creatorcontrib>Riehm, Hansjörg</creatorcontrib><creatorcontrib>Reiter, Alfred</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medical and pediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neth, Olaf</au><au>Seidemann, Kathrin</au><au>Jansen, Petra</au><au>Mann, Georg</au><au>Tiemann, Markus</au><au>Ludwig, Wolf-Dieter</au><au>Riehm, Hansjörg</au><au>Reiter, Alfred</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90</atitle><jtitle>Medical and pediatric oncology</jtitle><addtitle>Med. Pediatr. Oncol</addtitle><date>2000-07</date><risdate>2000</risdate><volume>35</volume><issue>1</issue><spage>20</spage><epage>27</epage><pages>20-27</pages><issn>0098-1532</issn><eissn>1096-911X</eissn><coden>MPONDB</coden><abstract>Background
Precursor B‐cell lymphoblastic lymphoma (PBLL) is a rare subtype of childhood non‐Hodgkin lymphoma (NHL). The purpose of our study was to investigate frequency and clinicopathological features of PBLL in children and to test prospectively the efficacy of an ALL‐type therapy for treatment of these patients.
Procedure
From October, 1986, to March, 1995, 1,075 patients up to 18 years of age suffering from all kinds of NHL were registered in the two consecutive multicenter studies NHL‐BFM 86 and 90. Of these, 27 patients were diagnosed with PBLL. Twenty‐one PBLL patients were treated according to a BFM‐ALL‐type protocol: an eight‐drug induction over 9 weeks was followed by an 8‐week consolidation including methotrexate 5 g/m2 ×4. Patients in stages I and II continued with maintenance up to a total therapy duration of 24 months, whereas patients in stages III and IV received an additional eight‐drug intensification and cranial radiotherapy (12 Gy for prophylaxis) after consolidation. Six PBLL patients were treated according to the BFM‐protocol for B‐NHL, stratified according to stage and tumor load and consisiting of two to six 5‐day courses of chemotherapy.
Results
The median age of the 27 patients with PBLL (18 boys, 9 girls) was 6.2 (range 0.7–15) years. Stages (St. Jude) were: I (n = 3), II (n = 7), III (n = 9), and IV (n = 8). Twenty‐one PBLL patients had nodal disease, 6 patients had subcutaneous manifestations, and 8 patients had bone marrow disease (<25% blasts). All patients achieved remission. With a median follow‐up time of 4.25 years, the estimated probability for event‐free survival (pEFS) at 10 years for the total group was 0.73 (SE 0.10). Five patients (2, 1, 1, and 1 patients at stages I, II, III, and IV, respectively) relapsed: 2 of 21 patients who were treated according to the ALL strategy and 3 of 6 who were treated according to the B‐NHL‐protocol.
Conclusions
PBLL accounts for 2.5% of childhood NHL. An ALL‐type therapy strategy appears to be superior to a short‐pulse B‐NHL protocol. Med. Pediatr. Oncol. 35:20–27, 2000. © 2000 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>10881003</pmid><doi>10.1002/1096-911X(200007)35:1<20::AID-MPO4>3.0.CO;2-L</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-1532 |
| ispartof | Medical and pediatric oncology, 2000-07, Vol.35 (1), p.20-27 |
| issn | 0098-1532 1096-911X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71237005 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asparaginase - administration & dosage Austria - epidemiology B-Lymphocytes Biological and medical sciences Chemotherapy Child Child, Preschool childhood therapy Cohort Studies Daunorubicin - administration & dosage Disease-Free Survival Female Germany - epidemiology Humans Infant lymphoblastic lymphoma Male Medical sciences Multicenter Studies as Topic Neoplasm Staging Pharmacology. Drug treatments precursor B-cell Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Prednisone - administration & dosage Prospective Studies Registries Survival Analysis Vincristine - administration & dosage |
| title | Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T02%3A57%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Precursor%20B-cell%20lymphoblastic%20lymphoma%20in%20childhood%20and%20adolescence:%20Clinical%20features,%20treatment,%20and%20results%20in%20trials%20NHL-BFM%2086%20and%2090&rft.jtitle=Medical%20and%20pediatric%20oncology&rft.au=Neth,%20Olaf&rft.date=2000-07&rft.volume=35&rft.issue=1&rft.spage=20&rft.epage=27&rft.pages=20-27&rft.issn=0098-1532&rft.eissn=1096-911X&rft.coden=MPONDB&rft_id=info:doi/10.1002/1096-911X(200007)35:1%3C20::AID-MPO4%3E3.0.CO;2-L&rft_dat=%3Cproquest_cross%3E71237005%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71237005&rft_id=info:pmid/10881003&rfr_iscdi=true |